<DOC>
	<DOCNO>NCT00167609</DOCNO>
	<brief_summary>To test efficacy safety two dos dehydroepiandrosterone ( DHEA ) adults myotonic dystrophy</brief_summary>
	<brief_title>Efficacy Safety DHEA Myotonic Dystrophy</brief_title>
	<detailed_description>Myotonic dystrophy inherit disorder affect 1 per 8000 adult . The disease characterize muscular dystrophy , myotonia , cardiac disorder , cognitive function impairment , hypersomnia , hair loss , endocrine disorder . Recent small study suggest DHEA treatment may improve muscle strength adult myotonic dystrophy . Thus , current study aim investigate safety efficacy prolong treatment DHEA adult myotonic dystrophy .</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Myotonic dystrophy ( genetically prove ) MDRS score 3 4 Age &lt; 18 year &gt; 70 year Pregnancy breastfeed Poor compliance treatment follow Inclusion clinical trial Severe cardiac disease : acute myocardial infarction precede 6 month , unstable heart failure , uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg 10 minute rest lie position ) , severe arteritis , past history thrombose embolic event , past history symptomatic arrhythmia ) Chronic renal failure Chronic liver disease Long term mechanical ventilation Any ongoing cancer Any underlying endocrine disorder Impaired swallow Previous treatment DHEA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>myotonic dystrophy</keyword>
	<keyword>hypersomnia</keyword>
	<keyword>dehydroepiandrosterone</keyword>
</DOC>